ClinicalTrials.gg
Sign In

Tetanus clinical trials

The registry lists 318 studies for Tetanus across more than 10 countries. 29 are recruiting or about to start. 85 of them are mainly about Tetanus (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.

Get an email when these change. Save the Tetanus studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
258
Recruiting
15
Status unknown
14
Not yet recruiting
13
Active, not recruiting
8
Terminated
6

Phase

Phase 3
141
Phase 4
60
Phase 2
48
Phase 1
29
Early Phase 1
1

Where

United States
62
China
46
Philippines
18
Korea, Republic of
16
Canada
16
Germany
15

Who runs them

GlaxoSmithKline (106) · Sanofi Pasteur, a Sanofi Company (60) · Sanofi (18) · CanSino Biologics Inc. (10) · National Institute of Allergy and Infectious Diseases (NIAID) (9) · LG Chem (7) · Merck Sharp & Dohme LLC (7) · Zhuhai Trinomab Pharmaceutical Co., Ltd. (5)

What is being tested here

Drugs under test in Tetanus studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Boostrix21221
Pentavac159
Poliovirus Vaccine, Inactivated112
Adacel0820
Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine0715
Diphtheria-Tetanus-Pertussis Vaccine079
Diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis -Haemophilus influenzae type b conjugate vaccine077
Tetanus Toxoid014
GSK2202083A004
V419044

Coming up

10phase 3 studies under way
7studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 7, phase 3 first

Who these studies take

Of the 15 Tetanus studies recruiting now, 7 (47%) set no upper age limit and 8 (53%) stop at 75 or younger. 9 (60%) take children under 18. 1 (7%) are for women only and 0 (0%) for men only; 10 (67%) take healthy volunteers.

Recruiting studies that take each age, of 15
AgeWomenMen
103 (20%)3 (20%)
188 (53%)7 (47%)
309 (60%)8 (53%)
409 (60%)8 (53%)
509 (60%)8 (53%)
658 (53%)7 (47%)
758 (53%)7 (47%)
857 (47%)6 (40%)

Across all 318 studies, recruiting or not: 78% stop at 75 or younger and 76% at 65; 76% take children; 5% are for women only and 1% for men only; 92% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Tetanus studies take

Of 55 phase 3 interventional studies under Tetanus, half reached primary completion within 12 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 25 mo2–17 · 11 studies——
Phase 312 mo6–21 · 55 studies12 mo6–21 · 54 studies—
Phase 422 mo6–30 · 19 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 11, 2026.

Started recruiting1

Newly registered2

Studies

Recruiting first, then most recently updated. Showing 50 of 318. Browse all 318 → or search them.